James Marsh
Concepts (487)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardium | 41 | 2008 | 441 | 2.290 |
Why?
| Calcium Channels, L-Type | 15 | 2008 | 63 | 1.570 |
Why?
| Myocardial Contraction | 34 | 2010 | 116 | 1.460 |
Why?
| Calcium Channels | 12 | 2006 | 59 | 1.010 |
Why?
| Stroke | 3 | 2019 | 526 | 0.930 |
Why?
| Genetic Therapy | 3 | 2009 | 121 | 0.930 |
Why?
| Platelet Function Tests | 2 | 2013 | 20 | 0.880 |
Why?
| Calcium | 29 | 2017 | 432 | 0.880 |
Why?
| Blood Platelets | 3 | 2017 | 269 | 0.860 |
Why?
| Purinergic P2Y Receptor Antagonists | 2 | 2013 | 30 | 0.850 |
Why?
| Platelet Aggregation Inhibitors | 3 | 2017 | 180 | 0.800 |
Why?
| Ion Channels | 9 | 2009 | 75 | 0.800 |
Why?
| Myocytes, Cardiac | 8 | 2010 | 137 | 0.740 |
Why?
| Brain Ischemia | 2 | 2019 | 169 | 0.700 |
Why?
| Rats | 34 | 2010 | 3415 | 0.700 |
Why?
| Fluorocarbons | 1 | 2019 | 52 | 0.680 |
Why?
| Heart | 16 | 2002 | 360 | 0.670 |
Why?
| Biomedical Research | 3 | 2018 | 240 | 0.660 |
Why?
| Neuroprotective Agents | 1 | 2019 | 125 | 0.640 |
Why?
| Research Personnel | 2 | 2018 | 69 | 0.640 |
Why?
| Personnel Selection | 1 | 2017 | 28 | 0.620 |
Why?
| Internal Medicine | 1 | 2017 | 24 | 0.620 |
Why?
| Receptors, Adrenergic, beta | 10 | 2000 | 41 | 0.610 |
Why?
| Heart Ventricles | 21 | 2010 | 271 | 0.600 |
Why?
| Cardiovascular Diseases | 4 | 2020 | 476 | 0.590 |
Why?
| Leadership | 1 | 2017 | 114 | 0.580 |
Why?
| Faculty, Medical | 1 | 2017 | 100 | 0.570 |
Why?
| Cells, Cultured | 36 | 2008 | 1737 | 0.550 |
Why?
| Animals | 63 | 2012 | 14385 | 0.550 |
Why?
| Physician's Role | 1 | 2014 | 55 | 0.500 |
Why?
| Sodium-Calcium Exchanger | 5 | 2004 | 7 | 0.480 |
Why?
| Education, Medical | 1 | 2014 | 107 | 0.470 |
Why?
| Chest Pain | 1 | 2013 | 65 | 0.450 |
Why?
| Ticlopidine | 1 | 2013 | 57 | 0.440 |
Why?
| Rats, Sprague-Dawley | 20 | 2005 | 1663 | 0.440 |
Why?
| Isoproterenol | 11 | 2001 | 52 | 0.430 |
Why?
| Muscle, Smooth, Vascular | 4 | 2006 | 140 | 0.430 |
Why?
| Coronary Disease | 3 | 2004 | 169 | 0.420 |
Why?
| RNA, Messenger | 16 | 2005 | 1202 | 0.420 |
Why?
| Coronary Artery Disease | 3 | 2012 | 329 | 0.410 |
Why?
| Angioplasty, Balloon, Coronary | 2 | 2012 | 167 | 0.400 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2010 | 150 | 0.390 |
Why?
| Acute Coronary Syndrome | 1 | 2012 | 91 | 0.380 |
Why?
| Excitation Contraction Coupling | 1 | 2010 | 3 | 0.380 |
Why?
| Calcium Signaling | 1 | 2010 | 59 | 0.370 |
Why?
| Cardiomegaly | 3 | 1998 | 38 | 0.360 |
Why?
| Calcium Channel Blockers | 7 | 1997 | 72 | 0.350 |
Why?
| Hypertension | 5 | 2020 | 564 | 0.330 |
Why?
| Protein Subunits | 4 | 2008 | 85 | 0.330 |
Why?
| Emergency Service, Hospital | 1 | 2013 | 539 | 0.330 |
Why?
| Transcription, Genetic | 5 | 2000 | 418 | 0.320 |
Why?
| Troponin I | 1 | 2008 | 20 | 0.310 |
Why?
| Molecular Mimicry | 1 | 2008 | 64 | 0.310 |
Why?
| Sarcoplasmic Reticulum | 4 | 2010 | 22 | 0.310 |
Why?
| Chick Embryo | 21 | 1993 | 79 | 0.300 |
Why?
| Subarachnoid Hemorrhage | 1 | 2008 | 65 | 0.300 |
Why?
| Drug Design | 1 | 2008 | 133 | 0.300 |
Why?
| Humans | 33 | 2020 | 54284 | 0.280 |
Why?
| Male | 31 | 2019 | 27334 | 0.270 |
Why?
| Muscle Proteins | 5 | 2007 | 307 | 0.270 |
Why?
| RNA Splice Sites | 1 | 2005 | 12 | 0.260 |
Why?
| Arteriosclerosis | 1 | 2004 | 59 | 0.250 |
Why?
| Testosterone | 6 | 2005 | 119 | 0.250 |
Why?
| Alternative Splicing | 1 | 2005 | 64 | 0.250 |
Why?
| Receptors, Adrenergic | 2 | 2001 | 14 | 0.250 |
Why?
| Stents | 3 | 2013 | 375 | 0.240 |
Why?
| Ventricular Function | 7 | 2005 | 20 | 0.240 |
Why?
| Time Factors | 8 | 2019 | 3213 | 0.240 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 158 | 0.240 |
Why?
| Predictive Value of Tests | 3 | 2013 | 1048 | 0.240 |
Why?
| Adrenergic beta-Agonists | 6 | 2001 | 43 | 0.230 |
Why?
| Receptors, Androgen | 3 | 2005 | 49 | 0.230 |
Why?
| United States | 7 | 2018 | 5217 | 0.230 |
Why?
| Muscle Cells | 1 | 2003 | 24 | 0.220 |
Why?
| Gene Expression Regulation | 6 | 2006 | 1062 | 0.220 |
Why?
| Muscle Fibers, Skeletal | 2 | 2001 | 78 | 0.220 |
Why?
| Glucose | 1 | 2005 | 366 | 0.220 |
Why?
| Treatment Outcome | 5 | 2019 | 5604 | 0.210 |
Why?
| Muscle Contraction | 1 | 2003 | 109 | 0.210 |
Why?
| Cell Membrane | 4 | 2017 | 278 | 0.210 |
Why?
| Risk Factors | 6 | 2020 | 3935 | 0.210 |
Why?
| Apoptosis | 2 | 2005 | 1300 | 0.210 |
Why?
| Drug Therapy, Combination | 2 | 2013 | 426 | 0.200 |
Why?
| Mutation | 1 | 2008 | 1501 | 0.190 |
Why?
| Female | 18 | 2019 | 28441 | 0.190 |
Why?
| Estrogens, Non-Steroidal | 1 | 2000 | 14 | 0.190 |
Why?
| 5' Untranslated Regions | 1 | 2000 | 33 | 0.190 |
Why?
| Plants | 1 | 2000 | 55 | 0.180 |
Why?
| Kinetics | 9 | 2010 | 692 | 0.180 |
Why?
| Adrenergic alpha-Agonists | 4 | 2001 | 18 | 0.180 |
Why?
| Maximum Tolerated Dose | 1 | 2019 | 37 | 0.180 |
Why?
| Isoflavones | 1 | 2000 | 83 | 0.180 |
Why?
| Phenylephrine | 4 | 2001 | 34 | 0.180 |
Why?
| Orchiectomy | 3 | 2004 | 38 | 0.180 |
Why?
| Administration, Intravenous | 1 | 2019 | 75 | 0.170 |
Why?
| Sulfonamides | 1 | 2000 | 146 | 0.170 |
Why?
| Middle Aged | 11 | 2019 | 13088 | 0.170 |
Why?
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 6 | 1993 | 10 | 0.170 |
Why?
| Angiotensin II | 3 | 1999 | 166 | 0.170 |
Why?
| Sex Factors | 2 | 2013 | 767 | 0.170 |
Why?
| Disability Evaluation | 1 | 2019 | 103 | 0.170 |
Why?
| Nitric Oxide Donors | 1 | 1998 | 12 | 0.170 |
Why?
| Multivariate Analysis | 2 | 2013 | 643 | 0.170 |
Why?
| Knee Prosthesis | 1 | 2019 | 56 | 0.170 |
Why?
| Drug Administration Schedule | 1 | 2019 | 401 | 0.160 |
Why?
| Recovery of Function | 1 | 2019 | 222 | 0.160 |
Why?
| Genetic Vectors | 2 | 2009 | 139 | 0.160 |
Why?
| Health Care Costs | 1 | 2019 | 171 | 0.160 |
Why?
| Animals, Newborn | 7 | 2007 | 396 | 0.160 |
Why?
| Logistic Models | 2 | 2013 | 995 | 0.150 |
Why?
| Women | 1 | 2017 | 36 | 0.150 |
Why?
| Risk Assessment | 2 | 2013 | 1361 | 0.150 |
Why?
| Double-Blind Method | 1 | 2019 | 742 | 0.150 |
Why?
| Promoter Regions, Genetic | 1 | 2000 | 520 | 0.150 |
Why?
| Schools, Medical | 1 | 2017 | 82 | 0.150 |
Why?
| Platelet Activation | 1 | 2017 | 50 | 0.150 |
Why?
| Epinephrine | 1 | 2017 | 97 | 0.150 |
Why?
| Minority Groups | 1 | 2017 | 136 | 0.140 |
Why?
| Signal Transduction | 3 | 2017 | 1753 | 0.140 |
Why?
| Nitric Oxide | 1 | 1998 | 298 | 0.140 |
Why?
| Receptors, Cholinergic | 1 | 1996 | 16 | 0.140 |
Why?
| Endothelium, Vascular | 3 | 2004 | 288 | 0.140 |
Why?
| Serotonin | 1 | 2017 | 159 | 0.140 |
Why?
| Delivery of Health Care | 1 | 2019 | 327 | 0.140 |
Why?
| Down-Regulation | 2 | 2008 | 388 | 0.140 |
Why?
| Benzofurans | 2 | 1992 | 18 | 0.130 |
Why?
| Education, Medical, Graduate | 1 | 2018 | 225 | 0.130 |
Why?
| Algorithms | 3 | 2013 | 697 | 0.130 |
Why?
| Myocardial Infarction | 1 | 1999 | 427 | 0.130 |
Why?
| Gene Expression Regulation, Developmental | 1 | 1996 | 151 | 0.130 |
Why?
| Cardiotonic Agents | 2 | 2010 | 95 | 0.130 |
Why?
| Myocytes, Smooth Muscle | 2 | 2008 | 92 | 0.130 |
Why?
| Ribonucleosides | 1 | 1994 | 2 | 0.130 |
Why?
| Aminoimidazole Carboxamide | 1 | 1994 | 3 | 0.130 |
Why?
| Arthroplasty, Replacement, Knee | 1 | 2019 | 282 | 0.130 |
Why?
| Thrombolytic Therapy | 2 | 2010 | 127 | 0.130 |
Why?
| Protein Isoforms | 3 | 2007 | 124 | 0.130 |
Why?
| Bradykinin | 3 | 1999 | 20 | 0.130 |
Why?
| DNA, Complementary | 2 | 2008 | 145 | 0.130 |
Why?
| Physicians | 1 | 2018 | 247 | 0.120 |
Why?
| Age Factors | 2 | 2013 | 1198 | 0.120 |
Why?
| Myocardial Reperfusion Injury | 1 | 1994 | 49 | 0.120 |
Why?
| Sodium | 4 | 1992 | 102 | 0.120 |
Why?
| Gene Expression | 5 | 2003 | 664 | 0.120 |
Why?
| Receptors, Adrenergic, beta-1 | 2 | 2004 | 7 | 0.120 |
Why?
| Receptors, Purinergic P2Y12 | 1 | 2013 | 13 | 0.120 |
Why?
| Cyclic AMP | 5 | 2000 | 106 | 0.120 |
Why?
| Dihydropyridines | 3 | 1993 | 10 | 0.120 |
Why?
| Arkansas | 1 | 2019 | 2100 | 0.110 |
Why?
| Therapy, Computer-Assisted | 1 | 2013 | 34 | 0.110 |
Why?
| Calsequestrin | 3 | 2007 | 3 | 0.110 |
Why?
| Drug Resistance | 1 | 2013 | 74 | 0.110 |
Why?
| Blood Pressure | 3 | 2006 | 587 | 0.110 |
Why?
| Ethers, Cyclic | 1 | 1992 | 4 | 0.110 |
Why?
| Educational Measurement | 1 | 2014 | 232 | 0.110 |
Why?
| Norepinephrine | 3 | 2001 | 119 | 0.110 |
Why?
| Tachycardia, Ventricular | 1 | 2013 | 43 | 0.110 |
Why?
| Smoking | 1 | 2017 | 556 | 0.110 |
Why?
| Beriberi | 1 | 2012 | 7 | 0.110 |
Why?
| Tachycardia, Supraventricular | 1 | 2013 | 39 | 0.110 |
Why?
| Ganglia, Sympathetic | 1 | 1992 | 3 | 0.110 |
Why?
| Base Sequence | 3 | 2005 | 719 | 0.110 |
Why?
| Defibrillators, Implantable | 1 | 2013 | 64 | 0.100 |
Why?
| Aged | 6 | 2019 | 10054 | 0.100 |
Why?
| Phosphodiesterase Inhibitors | 2 | 1988 | 27 | 0.100 |
Why?
| Cell Communication | 1 | 1992 | 72 | 0.100 |
Why?
| Drug Monitoring | 1 | 2012 | 85 | 0.100 |
Why?
| Decision Support Techniques | 1 | 2012 | 74 | 0.100 |
Why?
| Lipoproteins, LDL | 3 | 2004 | 195 | 0.100 |
Why?
| Odds Ratio | 1 | 2013 | 604 | 0.100 |
Why?
| Prospective Studies | 2 | 2019 | 2604 | 0.100 |
Why?
| Oxadiazoles | 2 | 1989 | 13 | 0.100 |
Why?
| Electrocardiography | 1 | 2013 | 290 | 0.100 |
Why?
| Incidence | 2 | 2008 | 1082 | 0.100 |
Why?
| International Normalized Ratio | 1 | 2010 | 29 | 0.100 |
Why?
| Diabetic Angiopathies | 1 | 2010 | 21 | 0.090 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 2 | 2001 | 56 | 0.090 |
Why?
| Cholesterol, LDL | 1 | 2010 | 41 | 0.090 |
Why?
| Blotting, Northern | 2 | 2000 | 108 | 0.090 |
Why?
| Evidence-Based Medicine | 1 | 2012 | 281 | 0.090 |
Why?
| Foramen Ovale, Patent | 1 | 2010 | 28 | 0.090 |
Why?
| Intracranial Hemorrhages | 1 | 2010 | 41 | 0.090 |
Why?
| Endarterectomy, Carotid | 1 | 2010 | 59 | 0.090 |
Why?
| Adenoviridae | 3 | 2007 | 58 | 0.090 |
Why?
| Thrombectomy | 1 | 2010 | 68 | 0.090 |
Why?
| 8-Bromo Cyclic Adenosine Monophosphate | 2 | 2000 | 3 | 0.090 |
Why?
| Action Potentials | 1 | 2010 | 131 | 0.090 |
Why?
| Gene Transfer Techniques | 1 | 2009 | 41 | 0.090 |
Why?
| Gene Targeting | 1 | 2009 | 32 | 0.090 |
Why?
| Warfarin | 1 | 2010 | 87 | 0.090 |
Why?
| Drug Prescriptions | 1 | 2010 | 89 | 0.090 |
Why?
| Percutaneous Coronary Intervention | 1 | 2013 | 338 | 0.080 |
Why?
| Prognosis | 2 | 2008 | 2118 | 0.080 |
Why?
| Rats, Inbred WKY | 1 | 2008 | 29 | 0.080 |
Why?
| Protein Modification, Translational | 1 | 2007 | 3 | 0.080 |
Why?
| Rats, Inbred SHR | 1 | 2008 | 33 | 0.080 |
Why?
| Protein Engineering | 1 | 2008 | 21 | 0.080 |
Why?
| Nifedipine | 4 | 1990 | 24 | 0.080 |
Why?
| Glasgow Coma Scale | 1 | 2008 | 48 | 0.080 |
Why?
| Cerebrovascular Disorders | 1 | 2008 | 53 | 0.080 |
Why?
| Mesenteric Arteries | 1 | 2008 | 45 | 0.080 |
Why?
| Medical Records | 1 | 2008 | 92 | 0.080 |
Why?
| Atrial Fibrillation | 1 | 2010 | 197 | 0.080 |
Why?
| Secondary Prevention | 1 | 2008 | 89 | 0.080 |
Why?
| Triiodothyronine | 1 | 1987 | 29 | 0.080 |
Why?
| Heart Diseases | 1 | 2010 | 237 | 0.080 |
Why?
| Thrombosis | 1 | 2010 | 243 | 0.080 |
Why?
| Anticoagulants | 1 | 2010 | 270 | 0.080 |
Why?
| Cholesterol | 1 | 2008 | 155 | 0.080 |
Why?
| Cell Culture Techniques | 2 | 2005 | 112 | 0.080 |
Why?
| Dogs | 3 | 2007 | 217 | 0.070 |
Why?
| Recombinant Fusion Proteins | 1 | 2008 | 206 | 0.070 |
Why?
| Cerebral Hemorrhage | 1 | 2008 | 102 | 0.070 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2013 | 486 | 0.070 |
Why?
| Adrenergic beta-Antagonists | 3 | 2017 | 105 | 0.070 |
Why?
| Heart Rate | 3 | 2001 | 357 | 0.070 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2007 | 131 | 0.070 |
Why?
| Pyridones | 1 | 1987 | 41 | 0.070 |
Why?
| Aorta | 2 | 2005 | 177 | 0.070 |
Why?
| 1-Methyl-3-isobutylxanthine | 4 | 1998 | 9 | 0.070 |
Why?
| Mitochondria, Heart | 2 | 2005 | 42 | 0.070 |
Why?
| Verapamil | 5 | 1994 | 23 | 0.070 |
Why?
| Angina Pectoris | 1 | 1986 | 22 | 0.070 |
Why?
| Binding Sites | 5 | 1990 | 440 | 0.070 |
Why?
| Vasodilator Agents | 1 | 1987 | 111 | 0.070 |
Why?
| Propranolol | 2 | 1994 | 78 | 0.070 |
Why?
| Adult | 9 | 2017 | 14207 | 0.070 |
Why?
| Arteriovenous Fistula | 1 | 1986 | 26 | 0.070 |
Why?
| Drug Delivery Systems | 1 | 2008 | 151 | 0.070 |
Why?
| Aortic Aneurysm | 1 | 1986 | 29 | 0.070 |
Why?
| Carotid Stenosis | 1 | 2006 | 61 | 0.070 |
Why?
| Carrier Proteins | 1 | 2007 | 359 | 0.070 |
Why?
| Vena Cava, Inferior | 1 | 1986 | 78 | 0.070 |
Why?
| Aortic Diseases | 1 | 1986 | 53 | 0.070 |
Why?
| Cytoskeleton | 1 | 1985 | 50 | 0.070 |
Why?
| Culture Media, Serum-Free | 1 | 2005 | 20 | 0.070 |
Why?
| Mannitol | 1 | 2005 | 15 | 0.070 |
Why?
| Alprenolol | 1 | 1985 | 1 | 0.070 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2005 | 21 | 0.070 |
Why?
| Restriction Mapping | 1 | 2005 | 32 | 0.070 |
Why?
| Cytoskeletal Proteins | 1 | 1985 | 58 | 0.070 |
Why?
| Hospital Mortality | 1 | 2008 | 465 | 0.060 |
Why?
| Tumor Necrosis Factors | 1 | 2004 | 10 | 0.060 |
Why?
| In Situ Nick-End Labeling | 1 | 2005 | 64 | 0.060 |
Why?
| Casein Kinase II | 1 | 2004 | 11 | 0.060 |
Why?
| Myocardial Ischemia | 1 | 2006 | 127 | 0.060 |
Why?
| Cloning, Molecular | 1 | 2005 | 198 | 0.060 |
Why?
| DNA Primers | 1 | 2005 | 225 | 0.060 |
Why?
| Muscle, Smooth | 1 | 2004 | 68 | 0.060 |
Why?
| Tissue Distribution | 1 | 2005 | 178 | 0.060 |
Why?
| bcl-X Protein | 1 | 2005 | 61 | 0.060 |
Why?
| Myosin Heavy Chains | 1 | 2004 | 19 | 0.060 |
Why?
| Cell Line | 1 | 2008 | 1153 | 0.060 |
Why?
| Coronary Artery Bypass | 2 | 2010 | 134 | 0.060 |
Why?
| Ligands | 1 | 2004 | 230 | 0.060 |
Why?
| Protein Structure, Tertiary | 1 | 2005 | 289 | 0.060 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2005 | 39 | 0.060 |
Why?
| Antihypertensive Agents | 2 | 2020 | 139 | 0.060 |
Why?
| Calcium Radioisotopes | 3 | 1989 | 6 | 0.060 |
Why?
| Gonadal Steroid Hormones | 2 | 2003 | 42 | 0.060 |
Why?
| Pyridines | 1 | 1985 | 137 | 0.060 |
Why?
| Androgens | 1 | 2004 | 68 | 0.060 |
Why?
| Temperature | 1 | 2004 | 177 | 0.060 |
Why?
| Osmolar Concentration | 3 | 1992 | 83 | 0.060 |
Why?
| Catecholamines | 2 | 1996 | 48 | 0.060 |
Why?
| Angiography | 1 | 1983 | 147 | 0.060 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 673 | 0.060 |
Why?
| Ion Channel Gating | 2 | 2006 | 47 | 0.060 |
Why?
| Luminescent Proteins | 1 | 2003 | 66 | 0.060 |
Why?
| Green Fluorescent Proteins | 1 | 2003 | 110 | 0.050 |
Why?
| Diagnosis, Differential | 2 | 2013 | 1136 | 0.050 |
Why?
| Coculture Techniques | 2 | 2003 | 160 | 0.050 |
Why?
| Cardiac Pacing, Artificial | 2 | 1994 | 31 | 0.050 |
Why?
| Vasodilation | 1 | 2003 | 106 | 0.050 |
Why?
| Pulmonary Embolism | 1 | 1983 | 106 | 0.050 |
Why?
| Receptors, Nicotinic | 2 | 1992 | 80 | 0.050 |
Why?
| Lovastatin | 2 | 1993 | 8 | 0.050 |
Why?
| Macrophages | 1 | 2004 | 405 | 0.050 |
Why?
| Proteins | 1 | 2005 | 376 | 0.050 |
Why?
| Systole | 2 | 1990 | 80 | 0.050 |
Why?
| Phenylalanine | 2 | 1999 | 125 | 0.050 |
Why?
| Electrophysiology | 3 | 1996 | 76 | 0.050 |
Why?
| Blotting, Western | 1 | 2003 | 683 | 0.050 |
Why?
| Chronotherapy | 1 | 2020 | 3 | 0.050 |
Why?
| Polymerase Chain Reaction | 2 | 2002 | 531 | 0.050 |
Why?
| Protein Kinase C | 1 | 2001 | 65 | 0.050 |
Why?
| Isoquinolines | 1 | 2000 | 25 | 0.050 |
Why?
| Isradipine | 3 | 1993 | 5 | 0.050 |
Why?
| Enzyme Inhibitors | 2 | 2000 | 446 | 0.050 |
Why?
| Culture Media | 3 | 1993 | 100 | 0.050 |
Why?
| Biological Transport | 1 | 2001 | 195 | 0.050 |
Why?
| Phytoestrogens | 1 | 2000 | 20 | 0.050 |
Why?
| Electrophoresis | 1 | 2000 | 18 | 0.050 |
Why?
| RNA, Antisense | 1 | 2000 | 10 | 0.050 |
Why?
| Genetic Complementation Test | 1 | 2000 | 55 | 0.050 |
Why?
| Plant Preparations | 1 | 2000 | 38 | 0.050 |
Why?
| Luciferases | 1 | 2000 | 57 | 0.050 |
Why?
| Molecular Sequence Data | 2 | 2000 | 980 | 0.050 |
Why?
| Inflammation | 1 | 2004 | 674 | 0.050 |
Why?
| Genes, Reporter | 1 | 2000 | 98 | 0.050 |
Why?
| Lung | 1 | 1983 | 507 | 0.050 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 124 | 0.050 |
Why?
| Up-Regulation | 3 | 2017 | 508 | 0.050 |
Why?
| Cell Nucleus | 1 | 2000 | 203 | 0.050 |
Why?
| Immunoblotting | 1 | 2000 | 134 | 0.050 |
Why?
| Stimulation, Chemical | 3 | 1990 | 33 | 0.050 |
Why?
| Decision Trees | 1 | 1999 | 26 | 0.040 |
Why?
| Ribosomal Protein S6 Kinases | 1 | 1999 | 10 | 0.040 |
Why?
| Stress, Mechanical | 1 | 1979 | 96 | 0.040 |
Why?
| Transfection | 1 | 2000 | 399 | 0.040 |
Why?
| Cardiomyopathies | 2 | 1990 | 129 | 0.040 |
Why?
| Canada | 1 | 2019 | 104 | 0.040 |
Why?
| Iloprost | 1 | 1998 | 4 | 0.040 |
Why?
| omega-N-Methylarginine | 1 | 1998 | 11 | 0.040 |
Why?
| Molsidomine | 1 | 1998 | 7 | 0.040 |
Why?
| Nitroprusside | 1 | 1998 | 12 | 0.040 |
Why?
| Sodium-Potassium-Exchanging ATPase | 2 | 1993 | 68 | 0.040 |
Why?
| Cyclic GMP | 1 | 1998 | 23 | 0.040 |
Why?
| Indomethacin | 1 | 1998 | 40 | 0.040 |
Why?
| Prosthesis Failure | 1 | 2019 | 113 | 0.040 |
Why?
| Consensus Development Conferences as Topic | 1 | 2018 | 13 | 0.040 |
Why?
| Hypertrophy, Left Ventricular | 1 | 1998 | 40 | 0.040 |
Why?
| Osteoarthritis, Knee | 1 | 2019 | 105 | 0.040 |
Why?
| Prosthesis Design | 1 | 2019 | 262 | 0.040 |
Why?
| Research Support as Topic | 1 | 2018 | 51 | 0.040 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2017 | 9 | 0.040 |
Why?
| Transglutaminases | 1 | 2017 | 17 | 0.040 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 79 | 0.040 |
Why?
| Patch-Clamp Techniques | 1 | 1997 | 148 | 0.040 |
Why?
| Platelet Aggregation | 1 | 2017 | 82 | 0.040 |
Why?
| Polysaccharides | 1 | 2017 | 57 | 0.040 |
Why?
| Heart Failure | 2 | 1993 | 541 | 0.040 |
Why?
| Cell Division | 3 | 2003 | 330 | 0.040 |
Why?
| Protein Transport | 1 | 2017 | 195 | 0.040 |
Why?
| Protein Biosynthesis | 1 | 1998 | 273 | 0.040 |
Why?
| Glycosylation | 2 | 2007 | 112 | 0.030 |
Why?
| Tandem Mass Spectrometry | 1 | 2017 | 248 | 0.030 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2017 | 377 | 0.030 |
Why?
| Pindolol | 2 | 1985 | 3 | 0.030 |
Why?
| Calibration | 2 | 1992 | 59 | 0.030 |
Why?
| GTP-Binding Proteins | 2 | 1993 | 94 | 0.030 |
Why?
| Purinergic P1 Receptor Antagonists | 1 | 1994 | 2 | 0.030 |
Why?
| Extracellular Space | 2 | 1993 | 43 | 0.030 |
Why?
| Fluorescent Dyes | 2 | 1992 | 116 | 0.030 |
Why?
| Theophylline | 1 | 1994 | 24 | 0.030 |
Why?
| Curriculum | 1 | 2018 | 429 | 0.030 |
Why?
| Transforming Growth Factor beta | 1 | 1994 | 158 | 0.030 |
Why?
| Case-Control Studies | 1 | 2017 | 1228 | 0.030 |
Why?
| Cardiomyopathy, Dilated | 1 | 1993 | 41 | 0.030 |
Why?
| Cell Separation | 3 | 2005 | 107 | 0.030 |
Why?
| Phosphorylation | 2 | 2005 | 614 | 0.030 |
Why?
| Receptors, Drug | 1 | 1993 | 6 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 2 | 1988 | 1476 | 0.030 |
Why?
| Digoxin | 1 | 1993 | 32 | 0.030 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2013 | 55 | 0.030 |
Why?
| Cytological Techniques | 1 | 1992 | 15 | 0.030 |
Why?
| Magnesium | 1 | 1992 | 42 | 0.030 |
Why?
| Homeostasis | 3 | 1990 | 223 | 0.030 |
Why?
| Urinary Tract Infections | 1 | 2012 | 52 | 0.030 |
Why?
| Ouabain | 3 | 1993 | 29 | 0.030 |
Why?
| Internship and Residency | 1 | 2018 | 501 | 0.030 |
Why?
| Potassium | 3 | 1993 | 60 | 0.030 |
Why?
| Disease Models, Animal | 2 | 1994 | 1639 | 0.030 |
Why?
| Aorta, Abdominal | 2 | 1994 | 45 | 0.020 |
Why?
| Malnutrition | 1 | 2012 | 83 | 0.020 |
Why?
| Fluoresceins | 1 | 1990 | 16 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2013 | 923 | 0.020 |
Why?
| Thyroid Hormones | 1 | 1990 | 18 | 0.020 |
Why?
| Phenethylamines | 1 | 1989 | 10 | 0.020 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 82 | 0.020 |
Why?
| Heart Transplantation | 1 | 1993 | 307 | 0.020 |
Why?
| Hospitals, Veterans | 1 | 2010 | 127 | 0.020 |
Why?
| Tritium | 2 | 1993 | 53 | 0.020 |
Why?
| Infant | 1 | 1998 | 3817 | 0.020 |
Why?
| Tetrodotoxin | 1 | 1989 | 11 | 0.020 |
Why?
| Cardiac Catheterization | 2 | 1983 | 258 | 0.020 |
Why?
| Sodium Channels | 1 | 1989 | 22 | 0.020 |
Why?
| Depression, Chemical | 1 | 1988 | 15 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2013 | 1304 | 0.020 |
Why?
| Bupivacaine | 1 | 1989 | 28 | 0.020 |
Why?
| Lidocaine | 1 | 1989 | 48 | 0.020 |
Why?
| Aerobiosis | 1 | 1988 | 16 | 0.020 |
Why?
| Amiloride | 1 | 1988 | 14 | 0.020 |
Why?
| Anaerobiosis | 1 | 1988 | 15 | 0.020 |
Why?
| Aspirin | 1 | 2010 | 127 | 0.020 |
Why?
| Free Radicals | 1 | 1988 | 31 | 0.020 |
Why?
| Catalase | 1 | 1988 | 74 | 0.020 |
Why?
| Oxygen | 2 | 1982 | 361 | 0.020 |
Why?
| Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 1 | 2007 | 1 | 0.020 |
Why?
| Leupeptins | 1 | 2007 | 8 | 0.020 |
Why?
| Tunicamycin | 1 | 2007 | 17 | 0.020 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2007 | 28 | 0.020 |
Why?
| Ryanodine Receptor Calcium Release Channel | 1 | 2007 | 12 | 0.020 |
Why?
| COS Cells | 1 | 2007 | 78 | 0.020 |
Why?
| Cell Membrane Permeability | 2 | 1987 | 28 | 0.020 |
Why?
| Superoxide Dismutase | 1 | 1988 | 125 | 0.020 |
Why?
| Sarcolemma | 1 | 1987 | 2 | 0.020 |
Why?
| Radioligand Assay | 1 | 1987 | 49 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2010 | 642 | 0.020 |
Why?
| Propanolamines | 1 | 1987 | 12 | 0.020 |
Why?
| Milrinone | 1 | 1987 | 10 | 0.020 |
Why?
| Binding, Competitive | 1 | 1987 | 113 | 0.020 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 151 | 0.020 |
Why?
| Proteasome Inhibitors | 1 | 2007 | 110 | 0.020 |
Why?
| Enkephalins | 1 | 1986 | 5 | 0.020 |
Why?
| Pulmonary Circulation | 2 | 1983 | 36 | 0.020 |
Why?
| Caspase 8 | 1 | 2005 | 16 | 0.020 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2005 | 19 | 0.020 |
Why?
| Cats | 1 | 2005 | 52 | 0.020 |
Why?
| Phenotype | 2 | 2003 | 820 | 0.020 |
Why?
| Membrane Potentials | 1 | 2006 | 139 | 0.020 |
Why?
| Heart Neoplasms | 1 | 1985 | 30 | 0.020 |
Why?
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2005 | 22 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2006 | 318 | 0.020 |
Why?
| bcl-2-Associated X Protein | 1 | 2005 | 73 | 0.020 |
Why?
| Testosterone Propionate | 1 | 2005 | 2 | 0.020 |
Why?
| Protein Conformation | 1 | 2006 | 226 | 0.020 |
Why?
| Guanylyl Imidodiphosphate | 1 | 1985 | 2 | 0.020 |
Why?
| Caspases | 1 | 2005 | 146 | 0.020 |
Why?
| Phosphoprotein Phosphatases | 1 | 2004 | 20 | 0.020 |
Why?
| Phosphates | 1 | 2004 | 51 | 0.020 |
Why?
| Carcinoma | 1 | 1985 | 153 | 0.020 |
Why?
| Ventilation-Perfusion Ratio | 1 | 1983 | 7 | 0.020 |
Why?
| Echocardiography | 2 | 1993 | 392 | 0.020 |
Why?
| Nitrendipine | 1 | 1983 | 2 | 0.020 |
Why?
| Diltiazem | 1 | 1983 | 11 | 0.010 |
Why?
| Evaluation Studies as Topic | 1 | 1983 | 107 | 0.010 |
Why?
| Radionuclide Imaging | 1 | 1983 | 130 | 0.010 |
Why?
| Thyroid Neoplasms | 1 | 1985 | 162 | 0.010 |
Why?
| Pressure | 1 | 2003 | 120 | 0.010 |
Why?
| Risk | 1 | 1983 | 343 | 0.010 |
Why?
| Sex Characteristics | 1 | 2004 | 214 | 0.010 |
Why?
| Organ Size | 1 | 2002 | 237 | 0.010 |
Why?
| Hemodynamics | 1 | 1983 | 290 | 0.010 |
Why?
| Cell Movement | 1 | 2003 | 271 | 0.010 |
Why?
| Heart Atria | 2 | 1993 | 57 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2007 | 820 | 0.010 |
Why?
| Dihydroalprenolol | 1 | 1980 | 3 | 0.010 |
Why?
| Retrospective Studies | 1 | 2013 | 6432 | 0.010 |
Why?
| Cricetinae | 2 | 1990 | 209 | 0.010 |
Why?
| Chronic Disease | 1 | 2003 | 614 | 0.010 |
Why?
| Oximetry | 1 | 1980 | 62 | 0.010 |
Why?
| Pulse | 1 | 1979 | 21 | 0.010 |
Why?
| Carotid Arteries | 1 | 1979 | 82 | 0.010 |
Why?
| Models, Biological | 1 | 2003 | 823 | 0.010 |
Why?
| Flavonoids | 1 | 1999 | 62 | 0.010 |
Why?
| Sirolimus | 1 | 1999 | 65 | 0.010 |
Why?
| Endothelium | 1 | 1998 | 45 | 0.010 |
Why?
| Postoperative Complications | 1 | 1983 | 1033 | 0.010 |
Why?
| Prazosin | 1 | 1994 | 11 | 0.010 |
Why?
| Atrial Natriuretic Factor | 1 | 1994 | 24 | 0.010 |
Why?
| Culture Media, Conditioned | 1 | 1994 | 52 | 0.010 |
Why?
| Constriction, Pathologic | 1 | 1994 | 104 | 0.010 |
Why?
| Turkeys | 1 | 1993 | 11 | 0.010 |
Why?
| Computers | 1 | 1994 | 45 | 0.010 |
Why?
| Virulence Factors, Bordetella | 1 | 1993 | 8 | 0.010 |
Why?
| Pertussis Toxin | 1 | 1993 | 9 | 0.010 |
Why?
| Fetal Blood | 1 | 1993 | 67 | 0.010 |
Why?
| Neoplasms | 1 | 1983 | 1316 | 0.010 |
Why?
| Cattle | 1 | 1993 | 224 | 0.010 |
Why?
| Calcium-Transporting ATPases | 1 | 1992 | 11 | 0.010 |
Why?
| Ventricular Function, Left | 1 | 1993 | 181 | 0.010 |
Why?
| Fibroblasts | 1 | 1994 | 386 | 0.010 |
Why?
| Analysis of Variance | 1 | 1993 | 635 | 0.010 |
Why?
| Stroke Volume | 1 | 1993 | 150 | 0.010 |
Why?
| Cell Survival | 1 | 1993 | 657 | 0.010 |
Why?
| Mesocricetus | 1 | 1990 | 8 | 0.010 |
Why?
| Fura-2 | 1 | 1990 | 3 | 0.010 |
Why?
| Lanthanum | 1 | 1990 | 3 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1992 | 767 | 0.010 |
Why?
| Diastole | 1 | 1990 | 79 | 0.010 |
Why?
| Fluorescence | 1 | 1990 | 53 | 0.010 |
Why?
| Reference Values | 1 | 1990 | 354 | 0.010 |
Why?
| Adenosine Diphosphate Ribose | 1 | 1989 | 8 | 0.010 |
Why?
| Atrial Function | 1 | 1989 | 7 | 0.010 |
Why?
| Cholera Toxin | 1 | 1989 | 16 | 0.010 |
Why?
| Oxidative Phosphorylation | 1 | 1987 | 57 | 0.000 |
Why?
| Glycolysis | 1 | 1987 | 73 | 0.000 |
Why?
| Enkephalin, Methionine | 1 | 1986 | 5 | 0.000 |
Why?
| Naloxone | 1 | 1986 | 61 | 0.000 |
Why?
| Oxygen Consumption | 1 | 1987 | 223 | 0.000 |
Why?
| Pulmonary Valve Stenosis | 1 | 1985 | 14 | 0.000 |
Why?
| Aging | 1 | 1990 | 784 | 0.000 |
Why?
| Adolescent | 1 | 1992 | 6897 | 0.000 |
Why?
| Coronary Circulation | 1 | 1980 | 62 | 0.000 |
Why?
| Regional Blood Flow | 1 | 1980 | 121 | 0.000 |
Why?
| Hemoglobins | 1 | 1980 | 126 | 0.000 |
Why?
|
|
Marsh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|